DC I CDER Meaning and
Definition
-
DC I CDER stands for "Division of Clinical Innovation, Center for Drug Evaluation and Research." It is a term used within the context of the U.S. Food and Drug Administration (FDA) and specifically refers to a specific division within the Center for Drug Evaluation and Research (CDER).
The Division of Clinical Innovation is responsible for promoting and supporting the advancement of innovative clinical trial designs and methodologies in evaluating the safety, effectiveness, and benefits of drugs. Their primary goal is to accelerate the development and approval of safe and effective drugs for patients.
The Division of Clinical Innovation focuses on fostering collaboration with various stakeholders, including academia, industry, patients, and other regulatory agencies, to enhance the clinical trial process. They aim to identify and address scientific and operational bottlenecks related to drug development through innovative approaches. This division strives to leverage cutting-edge science and technology to enhance clinical trial designs, biomarker-based drug development, and patient engagement.
As a part of the Center for Drug Evaluation and Research, the Division of Clinical Innovation plays a crucial role in shaping drug development and approval processes. Their work contributes to improving the efficiency and speed of evaluating new drugs while ensuring patient safety remains a top priority.
Common Misspellings for DC I CDER
- sc i cder
- xc i cder
- cc i cder
- fc i cder
- rc i cder
- ec i cder
- dx i cder
- dd i cder
- dc u cder
- dc j cder
- dc k cder
- dc o cder
- dc 9 cder
- dc 8 cder
- dc i xder
- dc i vder
- dc i fder
- dc i dder
- dc i cser
- dc i cxer
